63178 Federal Register / Vol. 69, No. 209 / Friday, October 29, 2004 / Notices 

2004, and all persons who requested the 

opportunity were permitted to appear in 

person or by counsel. 

The Commission transmitted its 

determination in this investigation to 

the Secretary of Commerce on October 

22, 2004. The views of the Commission 

are contained in USITC Publication 

3732 (October 2004), entitled Polyvinyl 

Alcohol from Taiwan: Investigation No. 

731–TA–1088 (Preliminary).

By order of the Commission.

Issued: October 25, 2004. 

Marilyn R. Abbott, 

Secretary to the Commission.

[FR Doc. 04–24205 Filed 10–28–04; 8:45 am] 

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

[EOIR No. 149] 

Executive Office for Immigration 

Review; Notice Extending Period To 

File Motions To Reopen Under the 

Barahona-Gomez v. Ashcroft

Settlement

AGENCY: Executive Office for 

Immigration Review (‘‘EOIR’’), Justice.

ACTION: Notice.

SUMMARY: This notice is to inform all 

parties that the motion to reopen period 

as defined in section (II)(B)(4) of the 

settlement agreement in BarahonaGomez v. Ashcroft, 243 F. Supp. 2d 

1029 (N.D. Cal. 2002), was extended to 

March 20, 2005. The full settlement 

agreement can be found at 243 F. Supp. 

2d 1029 (N.D. Cal. 2002), and also is 

reproduced on the EOIR Web site at 

http://www.usdoj.gov/eoir. The 

settlement agreement initially provided 

that the motion to reopen period was for 

eighteen (18) months from the date the 

Advisory Statement was published in 

the Federal Register. The Advisory 

Statement providing notice of the 

settlement was published in the Federal 

Register on March 20, 2003. See 68 FR 

13727. The motion to reopen period was 

to close on September 20, 2004. Under 

section (II)(B)(4) of the settlement 

agreement, if any eligible class member 

filed a motion to reopen proceedings 

under the settlement agreement within 

six months prior to September 20, 2004, 

the motion to reopen period is extended 

for an additional 180 days. This notice 

acknowledges that the deadline date 

was extended to March 20, 2005.

DATES: The deadline for filing motions 

to reopen under the settlement 

agreement was extended to March 20, 

2005.

FOR FURTHER INFORMATION CONTACT:

MaryBeth Keller, General Counsel, 

Office of the General Counsel, Executive 

Office for Immigration Review, 5107 

Leesburg Pike, Suite 2600, Falls Church, 

VA 22041, telephone (703) 305–0470.

Dated: October 15, 2004. 

Kevin D. Rooney, 

Director, Executive Office for Immigration 

Review.

[FR Doc. 04–24208 Filed 10–28–04; 8:45 am] 

BILLING CODE 4410–30–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to 21 CFR 1301.33(a), this is 

notice that on May 25, 2004, Cambrex 

North Brunswick Inc., Technology 

Centre of New Jersey, 661 Highway One, 

North Brunswick, New Jersey 08902, 

made application by renewal and on 

June 11, 2004 by letter to the Drug 

Enforcement Administration (DEA) for 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed:

Drug Schedule 

N-Ethylamphetamine (1475) ........ I 

Tetrahydrocannabinols (7370) ..... I 

2,5-Dimethoxyamphetamine 

(7396).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

4-Methoxyamphetamine (7411) ... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Codeine (9050) ............................. II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Methadone (9250) ........................ II 

Methadone Intermediate (9254) ... II 

Morphine (9300) ........................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such a substance 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such comments or objections 

may be addressed, in quintuplicate, to 

the Deputy Assistant Administrator, 

Office of Diversion Control, Drug 

Enforcement Administration, United 

States Department of Justice, 

Washington, DC 20537, Attention: DEA 

Federal Register Representative (ODLR) 

and must be filed no later than 

December 28, 2004.

Dated: October 1, 2004. 

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration.

[FR Doc. 04–24154 Filed 10–28–04; 8:45 am] 

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

EZRX, LLC Revocation of Registration 

On May 17, 2004, the Deputy 

Administrator of the Drug Enforcement 

Administration (DEA) issued an Order 

to Show Cause and Immediate 

Suspension of Registration to EXRX, 

LLC (EZRX) of Union, New Jersey. 

EZRX was notified of an opportunity to 

show cause as to why DEA should not 

revoke its DEA Certificate of 

Registration, BE8488783, as a retail 

pharmacy, and deny any pending 

applications for renewal or modification 

of such registration pursuant to 21 

U.S.C. 823(f) and 824(a)(4) for reason 

that its continued registration would be 

inconsistent with the public interest. 

EZRX was further notified that its DEA 

registration was immediately suspended 

as an imminent danger to the public 

health and safety pursuant to 21 U.S.C. 

824(d). 

The Order to Show Cause and 

Immediate Suspension alleged in sum, 

that EZRX was engaged in illegally 

dispensing controlled substances as part 

of a scheme in which controlled 

substances were dispensed by EZRX 

based on Internet orders placed by 

customers and approved by associated 

physicians, based solely on their review 

of Internet questionnaires and without 

personal contact, examination or bona 

fide physician/patient relationships. 

Such prescriptions were not issued ‘‘in 

the usual course of professional 

treatment’’ and violated 21 CFR 1306.04 

and 21 U.S.C. 841(a). This action was 

part of a nationwide enforcement 

operation by DEA titled Operation 

Pharmnet, which targeted online 

suppliers of prescription drugs, 

including owners, operators, 

pharmacists and doctors, who have 

illegally and unethically been marketing 

controlled substances via the Internet. 

According to the investigative file on 

May 26, 2004, the Order to Show Cause 

and Immediate Suspension of 

Registration was personally served by 

Special Agents and Diversion 

Investigators of the DEA at EZRX’s 

registered premises in Union, New 

Jersey. More than thirty days have 

passed since the Order to Show Cause